[1] |
中华医学会儿科学分会风湿病学组, 中国医师协会风湿免疫科医师分会儿科学组, 海峡两岸医药卫生交流协会风湿免疫病学专业委员会儿童学组, 等. 幼年皮肌炎诊断与治疗专家共识[J]. 中华实用儿科临床杂志, 2022, 37(10): 726-732.
|
[2] |
Matas-Garcia A, Milisenda JC, Espinosa G, et al. Gastrointestinal involvement in dermatomyositis[J]. Diagnostics (Basel), 2022, 12(5): 1200.
|
[3] |
许瑛杰, 周志轩, 侯俊, 等. 严重胃肠道受累的幼年皮肌炎4例病例系列报告[J]. 中国循证儿科杂志, 2019, 14(5): 355-358.
doi: 10.3969/j.issn.1673-5501.2019.05.007
|
[4] |
Leung AKC, Lam JM, Alobaida S, et al. Juvenile dermatomyositis: advances in pathogenesis, assessment, and management[J]. Curr Pediatr Rev, 2021, 17(4): 273-287.
doi: 10.2174/1573396317666210426105045
pmid: 33902423
|
[5] |
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7): 344-347.
doi: 10.1056/NEJM197502132920706
|
[6] |
Boccaletti V, Di Nuzzo S, Feliciani C, et al. An update on juvenile dermatomyositis[J]. G Ital Dermatol Venereol, 2014, 149(5): 519-524.
|
[7] |
Besnard C, Gitiaux C, Girard M, et al. Severe abdominal manifestations in juvenile dermatomyositis[J]. J Pediatr Gastroenterol Nutr, 2020, 70(2): 247-251.
doi: 10.1097/MPG.0000000000002575
|
[8] |
Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis[J]. Front Pediatr, 2018, 6: 284.
doi: 10.3389/fped.2018.00284
pmid: 30356795
|
[9] |
Xu Y, Ma X, Zhou Z, et al. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature[J]. Pediatr Rheumatol Online J, 2021, 19(1): 2.
doi: 10.1186/s12969-020-00486-x
pmid: 33407602
|
[10] |
Mamyrova G, Kleiner DE, James-Newton L, et al. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy[J]. Arthritis Rheum, 2007, 57(5): 881-884.
doi: 10.1002/(ISSN)1529-0131
|
[11] |
Schullinger JN, Jacobs JC, Berdon WE. Diagnosis and management of gastrointestinal perforations in childhood dermatomyositis with particular reference to perforations of the duodenum[J]. J Pediatr Surg, 1985, 20(5): 521-524.
pmid: 4057020
|
[12] |
See Y, Martin K, Rooney M, et al. Severe juvenile dermatomyositis complicated by pancreatitis[J]. Br J Rheumatol, 1997, 36(8): 912-916.
pmid: 9291863
|
[13] |
Day W, Gabriel C, Kelly RE Jr, et al. Juvenile derma-tomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review[J]. Rheumatol Int, 2020, 40(11): 1883-1890.
doi: 10.1007/s00296-019-04495-2
|
[14] |
Bhaskaran H, Balan S. Unusual cause for intestinal perforation in juvenile dermatomyositis[J]. BMJ Case Rep, 2019, 12(8): e229395.
doi: 10.1136/bcr-2019-229395
|
[15] |
Wang IJ, Hsu WM, Shun CT, et al. Juvenile dermato-myositis complicated with vasculitis and duodenal perforation[J]. J Formos Med Assoc, 2001, 100(12): 844-846.
|
[16] |
Schneider KO, Braeuninger C, Bergmann F, et al. The importance of computed tomography for the diagnosis of duodenal perforation in a paediatric patient with juvenile dermatomyositis[J]. Klin Padiatr, 2016, 228(4): 216-218.
doi: 10.1055/s-0042-101245
pmid: 27362413
|
[17] |
Besançon A, Brochard K, Dupic L, et al. Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units[J]. Rheumatology (Oxford), 2017, 56(10): 1814-1816.
doi: 10.1093/rheumatology/kex267
pmid: 28957568
|
[18] |
Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis[J]. Ann Rheum Dis, 2017, 76(2): 329-340.
doi: 10.1136/annrheumdis-2016-209247
pmid: 27515057
|
[19] |
Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up[J]. Clin Pediatr (Phila), 1987, 26(11): 561-566.
doi: 10.1177/000992288702601101
|
[20] |
Gitiaux C, De Antonio M, Aouizerate J, et al. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis[J]. Rheumatology (Oxford), 2016, 55(3): 470-479.
doi: 10.1093/rheumatology/kev359
pmid: 26424834
|
[21] |
Aouizerate J, De Antonio M, Bader-Meunier B, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis[J]. Rheumatology (Oxford), 2018, 57(5): 873-879.
doi: 10.1093/rheumatology/kex516
pmid: 29474663
|
[22] |
Wang X, Ding Y, Zhou Z, et al. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children[J]. Pediatr Rheumatol Online J, 2021, 19(1): 6.
doi: 10.1186/s12969-020-00492-z
pmid: 33407621
|
[23] |
管皖珍, 李国民, 李一帆, 等. 幼年型皮肌炎常见肌炎抗体与临床表型的关联分析[J]. 中国循证儿科杂志, 2021, 16(2): 93-98.
doi: 10.3969/j.issn.1673-5501.2021.02.003
|
[24] |
Kwiatkowska D, Reich A. The significance of autoantibodies in juvenile dermatomyositis[J]. Biomed Res Int, 2021, 2021: 5513544.
|
[25] |
Patwardhan A. The value of intravenous immunoglobulin therapy in idiopathic inflammatory myositis in the current transformed era of biologics[J]. Cureus, 2020, 12(2): e7049.
|
[26] |
Paik JJ, Lubin G, Gromatzky A, et al. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review[J]. Clin Exp Rheumatol, 2023, 41(2): 348-358.
|
[27] |
孙艳茹. 幼年皮肌炎的药物治疗进展[J]. 临床儿科杂志, 2022, 40(5): 395-400.
|